New Mass Spectrometry Method Finds Rare Bacterial Peptides That Could Guide Vaccine Design | Research

The takeaway

A data-independent mass spectrometry approach outperformed standard methods at detecting rare bacterial peptides on immune cells, scoring 150 million peptide candidates to find vaccine-relevant targets.

~150 million peptide precursors scored
The DIA-NN approach generated and searched proteome-wide predicted HLA class I peptide libraries, outperforming all other methods at identifying MHC class I peptides including rare bacterial epitopes.

What the researchers found

A new data-independent acquisition (DIA) mass spectrometry approach dramatically improved the detection of rare bacterial peptides displayed on immune cells. Using Listeria monocytogenes as a model pathogen, researchers showed that DIA workflows found additional human and bacterial immunopeptides missed by the standard data-dependent (DDA) method. Their most powerful approach used DIA-NN software to generate and search predicted peptide libraries covering approximately 150 million immunopeptide precursors, outperforming all other methods at identifying MHC class I peptides — the molecular targets that guide vaccine and immunotherapy design.

Why it matters

Finding the right peptide targets is the critical first step in designing vaccines and immunotherapies. Many important bacterial peptides are present in very low amounts on cell surfaces, making them invisible to standard detection methods. This improved approach can identify these rare peptide targets, potentially accelerating the development of vaccines against intracellular pathogens and expanding the pool of targets available for cancer immunotherapy.

The numbers in context

~150 million immunopeptide precursors scored · DIA outperformed DDA for low-abundant peptides · Listeria monocytogenes model pathogen

How the study worked

Researchers compared two mass spectrometry approaches — data-independent acquisition (diaPASEF) versus conventional data-dependent acquisition (ddaPASEF) — for profiling immunopeptides from cells infected with Listeria monocytogenes. They tested DIA spectrum-centric workflows and also used DIA-NN software to generate proteome-wide predicted HLA class I peptide spectral libraries, scoring approximately 150 million peptide precursors to identify both abundant and rare immunopeptides.

Who was studied

In vitro study using human cells infected with Listeria monocytogenes

What this study cannot tell us

This is a methods development study using a single model pathogen (Listeria monocytogenes). The approach needs validation across other pathogens and in clinical settings. The computational demands of searching 150 million precursors may limit accessibility. Peptide identification does not guarantee immunogenicity — the peptides still need biological validation to confirm they trigger immune responses.

How to read the evidence

This is a preliminary methods study demonstrating improved technical capability for peptide detection. While the mass spectrometry results are robust, the biological and clinical significance of the newly discovered peptides requires further validation through immunogenicity testing and in vivo studies.

When this study was published

Published in 2025, this represents the current cutting edge of immunopeptidomics methodology and reflects the latest advances in data-independent mass spectrometry approaches.

The bigger picture

Immunopeptidomics — the comprehensive study of peptides displayed on cell surfaces for immune recognition — is foundational to both vaccine development and cancer immunotherapy. By making it possible to detect rare peptide targets that standard methods miss, this technology could expand the repertoire of targets available for next-generation vaccines against intracellular pathogens and personalized cancer treatments.

Questions still open

Can this DIA approach be scaled to discover vaccine targets across a broad range of intracellular pathogens?
Do the newly identified low-abundant bacterial peptides actually trigger effective immune responses in vivo?
Could this technology be applied to find rare tumor-specific peptides for personalized cancer vaccines?

Common questions

What is immunopeptidomics and why does it matter for vaccines?

Immunopeptidomics is the study of all peptides displayed on cell surfaces by HLA molecules — the 'mugshots' your immune system uses to identify infected or cancerous cells. By finding these peptides, scientists can design vaccines that teach the immune system exactly what to look for, leading to more targeted and effective immunizations.

Why is it hard to find rare bacterial peptides on cell surfaces?

When bacteria infect cells, only small fragments get displayed on the cell surface, and some important targets are present in very low amounts. Standard mass spectrometry methods focus on the most abundant peptides and miss the rare ones. This new data-independent approach scans more comprehensively, catching peptides that previous methods overlooked.

Read the original research

Data-Independent Immunopeptidomics Discovery of Low-Abundant Bacterial Epitopes.

Journal of proteome research, 24(12), 6295-6304

View on PubMed ↗Publisher’s paper ↗

Citation

Willems, Patrick; Staes, An; Miret-Casals, Laia; Demichev, Vadim; Devos, Simon; Impens, Francis. (2025). Data-Independent Immunopeptidomics Discovery of Low-Abundant Bacterial Epitopes.. Journal of proteome research, 24(12), 6295-6304. https://doi.org/10.1021/acs.jproteome.5c00449